Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR mutation
i
Other names:
FGFR, Fibroblast Growth Factor Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR overexpression (7)
FGFR expression (2)
FGFR overexpression + MET overexpression (1)
FGFR overexpression (7)
FGFR expression (2)
FGFR overexpression + MET overexpression (1)
›
Associations
(21)
News
Trials
Search handles
@AndreaNecchi
@ArndtVogel
@Martin_AngelMD
@TiansterZhang
@VivekSubbiah
@apolo_andrea
@jgong15
@pashtoonkasi
@weoncologists
Search handles
@AndreaNecchi
@ArndtVogel
@Martin_AngelMD
@TiansterZhang
@VivekSubbiah
@apolo_andrea
@jgong15
@pashtoonkasi
@weoncologists
Filter by
Latest
8ms
In patients with FGFR-mutant urothelial cancer (UC), after immune checkpoint progression, do you use enfortumab vedotin (EV) or erdafitinib ? #ACScancerchat https://t.co/F6nmlNDAh5 (@VivekSubbiah)
8 months ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
10ms
Evan Yu examines how data presented at #ASCO23 from the PEACE-1 trial impacts treatment for prostate cancer patients. Next, Thomas Powles discusses the THOR & Norse trials & the implications for urothelial cancer patients with FGFR mutations. @tompowles1 https://t.co/Py5T6Ah4rf (@guconnectinfo)
10 months ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
10ms
.@DanielPetrylak urged patients with metastatic urothelial cancer be tested for FGFR mutations & considered for treatment with erdafitinib following the presentation of promising results from the phase 3 THOR #clinicaltrial. #ASCO23 @SmilowCancer @Yale_Urology @OncoAlert @YaleMed https://t.co/4djbcOfw7S (@YaleCancer)
10 months ago
Clinical • Metastases
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Balversa (erdafitinib)
1year
@GABOUALFA isoform switching from #IDH1 to #IDH2, evolution of #FGFR inh gatekeeper mutations, combination of #IO and locoregional therapies in #HCC, & potential viral etiology impact on #IO Now at @CSCancerCenter 4th Annual GI Tumor conf https://t.co/7s8rEqg0r4 @OncoAlert (@jgong15)
1 year ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
1year
In pts with FGFR-mutant🧬urothelial cancer, questions surround the tx sequence of Enfortumab Vedotin & Erdafitinib. Safety🛟profiles differ & ongoing trials may change landscape via @ASCO Daily News @OncoAlert 🚨 https://t.co/2pwOtrsWvt (@weoncologists)
1 year ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
1year
In patients with FGFR-mutant #urothelialcancer, after PD-1 progression, do you use enfortumab vedotin prior to erdafitinib or the reverse? @y_loriot addresses this debate for #ASCODailyNews: https://t.co/TwvwAfQs6q #blcsm (@ASCO)
1 year ago
Clinical • IO biomarker
|
FGFR (Fibroblast Growth Factor Receptor) • PD-1 (Programmed cell death 1)
|
FGFR mutation
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
over1year
Sameek Roychowdhury, MD, PhD, of @OhioStateMed, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma. #oncology https://t.co/G5yeAMXLY9 (@OncLive)
over 1 year ago
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
over1year
Co-mutational landscape of FGFR-altered #bladdercancer #glioma #iCCa may offer opportunities for further targeted therapies. Analysis from a large @FoundationATCG cohort. Congrats to all the team @ArndtVogel #ESMO2022 (@AndreaNecchi)
over 1 year ago
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
over1year
🔥Co-mutational spectrum of FGFR-F+ #cholangiocarcinoma deserves some thoughts! 👉in preclinical models efficacy of FGFRi is ⬇️ in context of strong co-🎯 https://t.co/TC5aUYVJya ❓in the clinic -> not yet conclusive, look for RAS, p53, CDKN2A/B @myESMO @enscca #livertwitter https://t.co/0pCiNOeNW7 (@ArndtVogel)
over 1 year ago
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGFR (Fibroblast Growth Factor Receptor) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • RAS (Rat Sarcoma Virus)
|
FGFR mutation
almost2years
PD-L1 expression and FGFR-mutations among Danish patients diagnosed with #metastatic urothelial #carcinoma - New study in APMIS J. by @TGrantzau, Birgitte Grønkær Toft, Linea C. Melchior, Johanna Elversang, Dag R. Stormoen, Lise H. Omland, @Helle_PP -> https://t.co/2yzSj0PjTp (@APMISJournal)
almost 2 years ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • FGFR mutation
2years
Watch @DrScottTagawa in a series of videos with @OncLive discussing metastatic #UrothelialCancer. Episode 1 covers prognostic gene testing for FGFR mutations: https://t.co/OAmpy7WOm6 (@cornellGUcancer)
2 years ago
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
2years
@DSolit @sloan_kettering discusses Why we need #NGS in patients with #bladdercancer? Look for FGFR mutations/fusions, germline testing, assist with tumor subtypes, platinum sensitivity biomarkers, etc) #GU22 @ASCO @OncoAlert @BladderCancerUS (@apolo_andrea)
2 years ago
Clinical • Next-generation sequencing
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation • FGFR fusion
2years
➡️ORR ✅FGFR fusions =25.0% ✅FGFR mutations =23.1% ✅partial responses in ➡️cholangiocarcinoma, head and neck, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, & non-small cell lung cancer @OncoAlert (@VivekSubbiah)
2 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation • FGFR fusion
2years
Pemigatinib was associated with clinical activity across tumors driven by FGFR fusions+mutations. These results prompted a registrational study in cholangiocarcinoma & phase II/III trials in many tumor types demonstrating the benefit of #PrecisionMedicine in early phase trials. (@VivekSubbiah)
2 years ago
Clinical • P2/3 data
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation • FGFR fusion
|
Pemazyre (pemigatinib)
2years
WATCH: A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer. @DrScottTagawa @WeillCornell @MDAndersonNews #oncology https://t.co/JMrRRlwCyW (@OncLive)
2 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
over2years
WATCH: @DrScottTagawa, @WeillCornell, and Arlene O. Siefker-Radtke, MD, @MDAndersonNews, discuss strategies that can be used to counsel patients on molecular testing for FGFR mutations and what to expect from treatment with erdafitinib. #pcsm #oncology https://t.co/Hb7jUnAPHZ (@OncLive)
over 2 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Balversa (erdafitinib)
over2years
@WCMEnglanderIPM Member Dr. Scott T. Tagawa (@DrScottTagawa) discusses current #prognostic and predictive testing assays used to detect #FGFR mutations in patients with #metastatic #urothelialcancer with @onclive #PrecisionMedicine https://t.co/4yzytCjAf6 (@WCMEnglanderIPM)
over 2 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
almost3years
.@MJavle, MD, of @MDAndersonNews discusses the @FDAOncology approval of infigratinib in FGFR-mutated cholangiocarcinoma. @US_FDA https://t.co/p00LiipXXT (@OncLive)
almost 3 years ago
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Truseltiq (infigratinib)
almost3years
Prostate metastatic ddr mutations and bladders fgfr (@AlisonBirtle)
almost 3 years ago
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
almost3years
@angiesmith_uro supporting the #PROOF302 study with adjuvant infigratinib for FGFR mutated urothelial cancer led by @montypal @PGrivasMDPhD #QED (@TiansterZhang)
almost 3 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Truseltiq (infigratinib)
3years
Diagnosis, testing and biomarkers in the individualisation of patient care with FGFR mutated bladder cancer - ecancer https://t.co/fLIE0qpbqQ (@AndreaNecchi)
3 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
3years
excellent presentation by @eugene_pietzak : Molecular characterization of NMIBC: FGFR mutations, DDR+ tumors, APOBEC....#GU21 @OncoAlert (@Martin_AngelMD)
3 years ago
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
3years
#GI21 on post-FGFR⛔️resistance. Please do 👀/🖍 💭 on my📝on #FGFR-fusion➕ #cholangiocarcinoma. 🆓 Available now👉🏾 https://t.co/W3lMsiJLuT Acquired 📈🔴🟠⚪️ #FGFR mutations ➡️ FGFR⛔️ #ctDNA 🩸🧬;📉chemo💡♻️. HETEROGENEITY: 1️⃣Intra-tumoral 2️⃣Temporal ⏳ #HPBCSM #LiquidBiopsies (@pashtoonkasi)
3 years ago
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation • FGFR fusion
3years
#GI21 interesting discussion on value of NGS 🔬as well as #liquidbiopsies #ctDNA which is theme of 👆🏾#Tweetorial. Post IDH1⛔️➡️ISOTYPE SWITCHING 1️⃣➡️2️⃣❗️; maybe role for other therapies; needs to be studied. Post FGFR⛔️➡️FGFR mutations; ❌fusions. Role for ?sequencing. (@pashtoonkasi)
3 years ago
Next-generation sequencing
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
over3years
🆕 Please do 👀/🖍 💭 on my📝on #FGFR-fusion➕ #cholangiocarcinoma. 🆓 Available now👉🏾https://t.co/uoefHQ10zM Acquired 📈🔴🟠⚪️ #FGFR mutations ➡️ FGFR⛔️ #ctDNA 🩸🧬;📉chemo💡♻️. All pts alive/doing well.🙌🏾 💡HETEROGENEITY: 1️⃣Intra-tumoral 2️⃣Temporal ⏳ #HPBCSM #LiquidBiopsies (@pashtoonkasi)
over 3 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
over3years
Policy in our center is that every pt with a metastatic solid tumor will have a comprehensive molecular profile test performed. This is the only way to detect the NTRKs and RETs, the FGFR fusions, Pol-e mutations etc. These are game changers for select patients. @OncoAlert (@agrothey)
over 3 years ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login